LEXINGTON, Mass., March 24, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, today announced
participation at the following conferences:
- The 7th Annual William Blair and Maidstone Life
Sciences conference "Cancer Immunotherapy Conference" at the
Apella, Event Space Alexandria Center in New York, NY. Agenus will participate in three
sessions:
- March 29 at 9:40 am: Robert B.
Stein, M.D., Ph.D., President, R&D will present at a
session titled "AutoSynVaxTM and
PhosphoSynVaxTM: Next Generation Neoepitope Heat Shock
Protein Vaccines" followed by a panel discussion on therapeutic
vaccines.
- March 30 at 10:40 am: Dr. Stein will present at a session
titled "Next Generation Immunomodulatory Antibodies: Optimizing
Therapeutic Impact."
- March 30 at 12:00 pm: Jean-Marie Cuillerot, M.D., Chief
Medical Officer, will participate in the lunch panel titled
"Challenges in Immuno-Oncology Drug Development."
- Jefferies Immuno-Oncology Summit at the Boston Harbor Hotel in
Boston, MA. Agenus will
participate in two sessions:
- March 30 at 3:00 pm: Jennifer
Buell, Ph.D., VP, Global Integrated R&D Operations, will
participate in a panel titled "Vaccines – Is There a Future?"
- March 30 at 3:45 pm: Nick
Wilson, Ph.D., Executive Director, Immuno-modulatory Drug
Discovery, will participate in a panel titled "Checkpoints - Which
Target has the Best Chances of Success?"
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing a number of combination
approaches that leverage a broad repertoire of antibody
therapeutics and proprietary cancer vaccine platforms. The Company
is equipped with a suite of antibody discovery platforms and a
state-of-the-art GMP manufacturing facility with the capacity to
support early phase clinical programs. Agenus is based in
Lexington, MA. For more
information, please visit www.agenusbio.com; information that may
be important to investors will be routinely posted on our
website.
Forward Looking Statements
This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding the upcoming presentations. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-participate-at-two-upcoming-immuno-oncology-conferences-300428924.html
SOURCE Agenus Inc.